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IgA Nephropathy S43progression group had more proteinuria, higher blood pressure, poorer renal
function, lower serumalbumin and lower hemoglobin.When casesweredivided
according to CKD stage, the results showed no significant difference of out-
comes among patients in CKD1-3a stages (P > 0.05). Their five-year renal sur-
vival rate was more than 95%. But patients in CKD3b-4 stage had worse
outcomes. The five-year renal survival rate of patients in CKD3b stage was
85.3%, while it was only 65.3% in CKD 4 stage.
Conclusion: Five-year renal survival rate of patients with primary IgAN was
92% in our hospital, and ten-year renal survival rate was 88%. Patients in
CKD3b or CKD4 stage at biopsy may have a lower renal survival rate and a
worse outcome. At the time of renal biopsy, patients with impaired renal
function, mass proteinuria, hypertension, anemia and low serum albumin
may have a greater risk of progressing to ESRD.http://dx.doi.org/10.1016/j.hkjn.2015.08.122
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Objective: Toll-like receptors (TLRs) are pattern associated receptors in
innate immunity that may be involved in the recognition of self antigens
and the production of pathogenic autoantibodies. The purpose of this study
was to examine the expression and clinical significance of Toll-like Receptor
9 (TLR9) in peripheral blood B lymphocytes and kidney tissues from IgA ne-
phropathy (IgAN) patients
Methods: We measured TLR9 expression in the peripheral blood B lympho-
cytes in 200 IgAN patients and 100 healthy controls. TLR9 expression in the pe-
ripheral blood B lymphocytes was measured by in Flow cytometry. TLR9
expression in the kidney tissues was detected by immunohistochemical stain-
ing. IPP6.0 softwarewas used to calculate the number of glomerulus crescent,
and SPSS 17.0 statistical software was used to perform the statistical analysis.
Results: Expression of TLR9 was increased in both peripheral blood B lympho-
cytes and kidney tissues from IgAN patients compared to the control groups. In
addition, the expressions of renal tissue TLR9 were found to be significant
negative correlated with urinary protein, and positive correlated with the
number of glomerulus crescent and glomerular filtration rate.
Conclusion: Elevated TLR9 levels were associated with the severity of renal
function injury in IgAN patients. These findings help to clarify some of the
clinical observations in the management of IgAN, and may highlight future
directions for research.http://dx.doi.org/10.1016/j.hkjn.2015.08.123
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Objective: Accurate estimation of the risk of end stage renal disease (ESRD)
at the time of diagnosis of IgA nephropathy (IgAN) is critical for guiding case
management, patient education, and timely planning of dialysis and trans-
plantation. The aim of this study was to develop and validate a simple pre-
diction tool for bedside risk estimation of end-stage renal failure (ESRD) in
patients with IgAN.
Methods: A retrospective cohort study was performed. Biopsy-proven IgAN
patients with estimated glomerular filtration rate value higher than 15 ml/
min/1.73 m2 at the time of renal biopsy were recruited. Clinical character-
istics were collected during routine clinical practice. ESRD was defined by a
need for renal replacement therapy (dialysis or renal transplantation). Cox
regression was carried out to predict patient risk of ESRD and established
a risk scoring system.
Results: We analyzed 1,586 primary IgAN cases across 2 major nephrology
centers with a mean follow-up time of 44.5 months (range 12e246 months),
followed by validation in an independent cohort of 1,092 additional patients
across 5 major nephrology centers. In total, the progression data were
analyzed for 2,678 patients, of which 212 (8%) reached ESRD during
follow-up. We identified five baseline clinical variables with an independent
effect on the risk of ESRD, including gender, age, eGFR, urine protein and
hemoglobin. We propose a simple bedside prediction tool based on our
model. In the validation cohort, this model was more accurate than a
simpler model that included eGFR, serum albumin, hemoglobin and systolic
blood pressure [integrated discrimination improvement, 9.4% (4.9%, 13.9%);
c Statistic 0.92 vs 0.90; and net reclassification improvement 9.2% (-4.1%,
22.6%)].
Conclusion: Our prediction tool is simple, accurate, and readily applicable
to clinical practice.http://dx.doi.org/10.1016/j.hkjn.2015.08.124
0372
Association of ABO Blood Group with Progression of IgA Nephropathy
Meng Yang, Jingyuan Xie, Yan Ouyang, Xiaoyan Zhang, Xiao Li, Wen Zhang,
Weiming Wang, Nan Chen
Department of Nephrology, Ruijin Hospital, Shanghai Jiaotong University
School of Medicine, Shanghai, China
Objective: The aim of this study is to explore its association with progression
of IgA nephropathy (IgAN).
Methods: Biopsy-proven primary IgAN patients with at least eGFR  15 ml/
min/1.73 m2 at the time of biopsy and follow-up time  1 year were retro-
spectively recruited. Clinical, histological and progression data were
recorded. Renal tissue was semi-quantitative scoredaccording to the Oxford
scoring system. ABO blood group was determined by standard erythrocyte
antiserum agglutination method. All patients were divided into B antigen
group (type B and AB) and non-B antigen group (type A and O) based on their
ABO types.
Results: Among the 919 IgAN patients recruited in this study, 252 patients
were type A (27.4%), 273 were type B (29.7%), 93 were type AB (10.1%)
and 301 were type O (32.8%). When renal biopsy was performed, patients
in B antigen group had higher eGFR (81.28 vs. 72.47 ml/min/1.73 m2), lower
systolic blood pressure (sbp) (125.26 vs. 128.77 mmHg) and uric acid (6.19 vs.
6.52 mg/dl) than patients in non-B antigen group. No significant difference
was detected in histological lesions between these two groups. Totally,
124 patients (13.5%) progressed to end-stage renal disease (ESRD) after a
median follow-up period of 57.46 months, including 42 (16.7%) type A, 23
(8.4%) type B, 3 (3.2%) type AB and 56 (18.6%) type O patients. Kaplan-Meier
analysis showed that median ESRD-free survival time of patients in B antigen
group was significantly longer than patients in non-B antigen group
(159.05 4.94 months vs. 143.09 6.38 months, p < 0.001). Furthermore,
patients in B antigen group were associated with a decreased risk of ESRD
(HR Z 0.51, 95% CI 0.31e0.83) after being adjusted by age, sex, clinical
and historical indicators (SBP, eGFR, blood urea nitrogen, serum albumin,
uric acid, serum triglycerides, hemoglobin, serum C3, urine protein and Ox-
ford Classification T).
Conclusion: Our data suggest that B antigen had an independent protective
effect against the progression of IgAN.
Table 1 Baseline characteristics of IgAN patients.
Variables Blood group P value
B antigen group (n Z 366) non-B antigen group (n Z 553)
AB (n Z 93) B (n Z 273) p value A (n Z 252) O (n Z 301) p value
Follow-up (months) 52.43  37.92 59.57  41.24 0.14 58.06  41.78 56.6  40.67 0.68 0.51
Age at biopsy (years) 35.3  11.97 36.76  11.9 0.31 37.08  13.37 37.1  11.74 0.99 0.64
Gender (Male: Female) 0.58 (34:59) 0.81 (122:151) 0.17 1.25 (140:112) 1.05 (154:147) 0.30 0.005*
Body mass index (kg/m2) 22.72  3.47 22.73  3.22 0.99 23.24  3.41 23.26  3.43 0.95 0.20
Serum creatinine (mg/dl) 0.96 (0.49e4.06) 1.05 (0.44e4.24) 0.65 1.13 (0.49e4.12) 1.2 (0.35e5.18) 0.37 <0.001*
eGFR (mL/mm/1.73 m2) 83.55  37.69 80.51  33.63 0.49 73.67  33.24 71.46  34.25 0.44 0.001*
CKD stage 1 (%) 45 (48.4%) 113 (41.4%) 0.06 88 (34.9%) 91 (30.2%) 0.27 0.006*
CKD stage 2 (%) 13 (14.0%) 74 (27.1%) 66 (26.2%) 84 (27.9%)
CKD stage 3 (%) 29 (31.2%) 65 (23.8%) 77 (30.6%) 87 (28.9%)
CKD stage 4 (%) 6 (6.5%) 21 (7.7%) 21 (8.3%) 39 (13.0%)
SBP (mm Hg) 125.04  16.77 125.33  16.55 0.88 129.5  18.68 128.16  17.09 0.38 0.02*
DBP (mm Hg) 78.16  12.57 80  11.39 0.19 81.41  12.48 82.15  12.57 0.49 0.02*
MAP (mm Hg) 93.79  13.32 95.11  12.26 0.38 97.44  13.55 97.48  13.19 0.97 0.02*
Hypertension (%) 22/93 (23.7%) 82/273 (30%) 0.24 100/252 (39.7%) 121/301 (40.2%) 0.90 0.003*
Blood urea nitrogen (mg/dL) 14.29 (7.28e53.5) 15.13 (6.44e54.06) 0.32 16.95 (5.88e120.45) 17.65 (5.88e76.47) 0.14 0.001*
Serum uric add (mg/dL) 6.09  1.61 6.22  1.73 0.51 6.58  1.86 6.48  1.73 0.49 0.03*
Hyperuricemia (%) 30/93 (32.3%) 102/272 (37.5%) 0.36 98/252 (38.9%) 123/300 (41.0%) 0.61 0.48
Serum total protein (g/dL) 6.19  0.88 6.28  0.88 0.42 6.29  0.91 6.26  0.89 0.66 0.82
Serum albumin (g/dL) 3.5 (1.8e5) 3.6 (0.9e5) 0.12 3.6 (0.7e4.9) 3.6 (1e4.9) 0.72 0.45
Hypoalbuminemia (%) 19/93 (20.4%) 48/272 (17.6%) 0.55 41/252 (16.3%) 44/300 (14.7%) 0.60 0.57
Serum triglycerides (mg/dL) 147.03 (39.86e654.56) 159.43 (42.52e1140.83) 0.19 176.26 (40.74e752.88) 147.48 (50.49e1034.54) 0.05* 0.14
Serum cholesterol (mg/dL) 190.64 (100.15e474.48) 193.74 (32.1e512.76) 0.75 196.25 (59.55e576.57) 192.38 (32.1e696.83) 0.67 0.93
Hemoglobin (g/dl) 12.83  1.71 13.15  1.91 0.15 12.84  1.98 12.8  2.11 0.83 0.14
Anemia (%) 38/93 (40.9%) 98/272 (36.0%) 0.41 110/252 (43.7%) 130/300 (43.3%) 0.94 0.24
Plt (103/mm3) 214.86  60.73 218.92  63.24 0.59 216.73  61.55 215.29  64.58 0.79 0.91
WBC (103/mm3) 7.11 (4.3e19) 7.1 (3.5e17.7) 0.54 7.3 (3.7e20.1) 7.1 (3.2e22.8) 0.78 0.84
Serum IgA (mg/dL) 317.5 (70.3e688) 325 (112e706) 0.56 320.5 (99e930) 322.5 (68e781) 0.81 0.93
Serum IgM (mg/dL) 118 (30e400) 126.5 (25e714) 0.90 116.5 (29e408) 126 (14e479) 0.17 0.36
Serum IgG (mg/dL) 1123.95  445.46 1105.83  358.08 0.70 1110.19  331.67 1128.1  346.69 0.55 0.89
Serum C3 (mg/dL) 102 (61.9e198) 104 (42.7e204) 0.64 101 (62e218) 100 (55e181) 0.29 0.23
Serum C4 (mg/dL) 22.1 (12e56) 24.45 (10.25e63) 0.11 23.4 (10.6e75.7) 23.7 (8e80) 0.58 0.42
Urine protein excretion (g/24 h) 1.08 (0.03e8.53) 1.02 (0.04e12.7) 0.69 1.18 (0.02e10.1) 1.2 (0.05e13.91) 0.32 0.26
ESRD (%) 3/93 (3.2%) 23/273 (8.4%) 0.09 42/252 (16.7%) 56/301 (18.6%) 0.55 <0.001*
ACEI or ARB treatment (%) 73/93 (78.5%) 235/273 (86.1%) 0.08 213/252 (84.5%) 258/301 (85.7%) 0.70 0.33
Glucocorticoid treatment (%) 61/93 (65.6%) 150/273 (54.9%) 0.07 143/252 (56.7%) 166/301 (55.1%) 0.71 0.31
Data are presented as n (%) or mean  SD or median and interquartile range. eGFR: estimated glomerular filtration rate; SBP: systolic blood pressure; DBP:
diastolic blood pressure; MAP: mean arterial pressure; PLT: platelet count; WBC: white blood cell count; Ig: immunoglobulin; C: complement; ACEI: angio-
tensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; *p < 0.05.
S44 IgA NephropathyFigure 1. Kaplan-Meier outcome-free survival curves. Patients from B an-
tigen group (black) versus non-B antigen group (red).http://dx.doi.org/10.1016/j.hkjn.2015.08.1250373
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Background: A large number of crescent formation (> 50% of all glomeruli)
often lead to rapidly progressive renal failure in patients with IgA nephrop-
athy (IgAN). However, little is known of clinical outcomes of moderate cres-
cent formation (10e50% of all glomeruli) in IgAN. The aim of this study is to
investigate clinical characteristics and outcomes of IgAN patients with mod-
erate crescent formation.
Methods: Primary biopsy-proven IgAN patients from two extend renal centers
in Shanghai and Beijingwere enrolled. Patients secondary to systemic diseases
or followed up less than 12 months were excluded. Patients were classified to
mild (1e10%) or moderate (11e50%) crescent group based on the percentage
of glomeruli with crescents. Baseline data were collected at the time of renal
biopsy and during follow-up, including gender, age, mean arterial pressure
(MAP), proteinuria, serum creatinine, histological parameters and therapy.
Results: A total of 1145 patients were recruited. There were 265 and 254 pa-
tients in mild and moderate crescent group respectively. Compared to pa-
tients without crescent formation, patients in mild or moderate crescent
